Signals
Tirzepatide’s Next Question: What Lies Beyond Cardiovascular Events?
New SURPASS-CVOT analyses presented at EASD 2026 suggest that tirzepatide may offer benefits beyond conventional cardiovascular endpoints, including lower infection-related mortality and better patient-reported physical functioning compared with dulaglutide.
Why some “resistant” hypertension isn’t resistant at all, and what cardiology might be missing
Desmoid Tumours Are Not Benign to the People Living With Them
When Dementia Takes Speech, Trials Must Catch Up
Child Mental Health Access Still Depends on the Facility
Europe Built Seasonal COVID Campaigns. Most Older Adults Were Not Reached.
Treating hypertension in pregnancy is possible. Making it routine care is the policy challenge
Ultra-processed food may leave a metabolic fingerprint in the blood.
Huntington’s Gets Another Chance at Proof
New global heart failure definition exposes a policy gap: systems still diagnose too late and treat too narrowly
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.